interferon alpha (alpha)

(redirected from interferon alpha a)

in·ter·fer·on al·pha (α)

(in'tĕr-fēr'on-al'fă)
The major interferon made by virus-induced leukocytes; several different subtypes exist that are elaborated by leukocytes in response to viral infection or to stimulation with double-stranded RNA.
References in periodicals archive ?
Amarillo Biosciences, founded in 1984, is a pioneer in the research of low dose orally-administered interferon alpha as a treatment for a variety of conditions including Sjogren's syndrome, fibromyalgia syndrome, Behcet's disease, hepatitis B and C, and opportunistic infections in patients who are HIV positive.
Nasdaq: AMAR) today announced that enrollment has opened for its final Phase 3 clinical trial on the use of low dose oral interferon alpha as a treatment for dry mouth in Sjogren's syndrome patients.
Cummins, President and CEO of Amarillo Biosciences, stated, "I am extremely pleased to have executed the budget agreement with PPD Pharmaco in order to complete our Phase 3 clinical trials for the use of low dose oral interferon alpha as a treatment for dry mouth in Sjogren's syndrome patients.
Amarillo Biosciences, founded in 1984, is a world leader in the development of oral interferon alpha as a treatment for a variety of conditions including Sjogren's syndrome, fibromyalgia, opportunistic infections in patients who are HIV positive, hepatitis B and hepatitis C.
Amarillo Biosciences, founded in 1984, is one of the world's leading companies developing oral interferon alpha as a treatment for a variety of autoimmune and immune deficiency diseases including Sjogren's syndrome, fibromyalgia, opportunistic infections in patients who are HIV positive, hepatitis B and hepatitis C.
NASDAQ:AMAR) announced today that a study will commence this month to test low dose oral interferon alpha as a combination treatment with high dose injectable interferon alpha in hepatitis C patients in Canada and Mexico.
is one of the leading companies developing and currently testing oral interferon alpha as a treatment of a variety of diseases including oral mucositis in cancer patients, hepatitis B, hepatitis C, myeloproliferative diseases and Sjogren's Syndrome.
is one of the leading companies developing oral interferon alpha as a treatment of a variety of diseases including oral mucositis in cancer patients, hepatitis B, hepatitis C and Sjogren's Syndrome.
is one the leading companies developing oral interferon alpha as a treatment of a variety of diseases including oral mucositis in cancer patients, Hepatitis B, Hepatitis C and Sjogren's Syndrome.